Scribe Therapeutics Inc. (SCTX)Healthcare | Biotechnology | Alameda, United States | NasdaqGM
28.44 USD
-0.40
(-1.387%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 28.00 -0.44 (-0.440%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:08 a.m. EDT
The immediate outlook is neutral due to a lack of statistical data to confirm short-term trends, though the stock recently rallied from lows near $22 to $34, suggesting some buying interest. However, the long-term investment case is severely compromised by deteriorating fundamentals: revenue has collapsed by 87%, gross margins are deeply negative at -54%, and the company is burning significant cash with no path to profitability visible in the forward estimates. The balance sheet is fragile with a current ratio below 1.0 and negative book value, indicating the company is likely relying on capital markets or dilution to survive. With no dividend history and a business model currently eroding value rather than generating it, this security offers no safety margin for investors. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 14.87 |
| Market Cap | 536,503,136 |
| Forward P/E | -8.24 |
| Profit Margins | -98.48% |
| Website | https://www.scribetx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.52029526 |
| Address1 | 1,150 Marina Village Pkwy |
| All Time High | 39.6 |
| All Time Low | 17.31 |
| Ask | 18.76 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 305,760 |
| Average Daily Volume3 Month | 237,787 |
| Average Volume | 237,787 |
| Average Volume10Days | 305,760 |
| Bid | 14.57 |
| Bid Size | 4 |
| Book Value | -64.311 |
| City | Alameda |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.44 |
| Current Ratio | 0.657 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 34.6399 |
| Day Low | 27.99 |
| Display Name | Scribe Therapeutics |
| Ebitda | -29,977,000 |
| Ebitda Margins | -0.82622004 |
| Enterprise To Ebitda | -6.243 |
| Enterprise To Revenue | 5.158 |
| Enterprise Value | 187,155,168 |
| Eps Current Year | -5.925 |
| Eps Forward | -3.45 |
| Eps Trailing Twelve Months | -2.02 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 25.04875 |
| Fifty Day Average Change | 3.3912506 |
| Fifty Day Average Change Percent | 0.13538602 |
| Fifty Two Week Change Percent | 52.029526 |
| Fifty Two Week High | 39.6 |
| Fifty Two Week High Change | -11.159998 |
| Fifty Two Week High Change Percent | -0.28181815 |
| Fifty Two Week Low | 17.31 |
| Fifty Two Week Low Change | 11.130001 |
| Fifty Two Week Low Change Percent | 0.642981 |
| Fifty Two Week Range | 17.31 - 39.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,785,159,000,000 |
| Float Shares | 892,583 |
| Forward Eps | -3.45 |
| Forward P E | -8.243479 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 89 |
| Fullday Change | -0.4 |
| Fullday Change Percent | -1.38696 |
| Fullday Price | 28.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.54647 |
| Gross Profits | -19,827,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11529 |
| Held Percent Institutions | 0.53185004 |
| Implied Shares Outstanding | 18,864,386 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-07-24 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California. |
| Long Name | Scribe Therapeutics Inc. |
| Market | us_market |
| Market Cap | 536,503,136 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_642070737 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -35,730,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 540,276,015 |
| Number Of Analyst Opinions | 3 |
| Open | 28.78 |
| Operating Cashflow | -39,147,000 |
| Operating Margins | -5.56516 |
| Payout Ratio | 0.0 |
| Phone | 510 626 8587 |
| Post Market Change | -0.44000053 |
| Post Market Change Percent | -1.5471185 |
| Post Market Price | 28.0 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 28.84 |
| Price Eps Current Year | -4.7999997 |
| Price Hint | 2 |
| Price To Book | -0.44222608 |
| Price To Sales Trailing12 Months | 14.787033 |
| Profit Margins | -0.98478997 |
| Quick Ratio | 0.643 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.4 |
| Regular Market Change Percent | -1.38696 |
| Regular Market Day High | 34.6399 |
| Regular Market Day Low | 27.99 |
| Regular Market Day Range | 27.99 - 34.6399 |
| Regular Market Open | 28.78 |
| Regular Market Previous Close | 28.84 |
| Regular Market Price | 28.44 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 201,706 |
| Revenue Growth | -0.87 |
| Revenue Per Share | 14.87 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 18,864,386 |
| Shares Percent Shares Out | 0.0150999995 |
| Shares Short | 263,070 |
| Short Name | Scribe Therapeutics Inc. |
| Short Ratio | 0.65 |
| Source Interval | 15 |
| State | CA |
| Symbol | SCTX |
| Target High Price | 60.0 |
| Target Low Price | 50.0 |
| Target Mean Price | 56.0 |
| Target Median Price | 58.0 |
| Total Cash | 49,731,000 |
| Total Cash Per Share | 20.148 |
| Total Debt | 46,332,000 |
| Total Revenue | 36,282,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.02 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.04875 |
| Two Hundred Day Average Change | 3.3912506 |
| Two Hundred Day Average Change Percent | 0.13538602 |
| Type Disp | Equity |
| Volume | 201,706 |
| Website | https://www.scribetx.com |
| Zip | 94,501 |